Give Kids a Chance Act of 2025

Key Provisions

• Extends the rare pediatric disease priority review voucher program until September 30, 2029.
• Lets drug companies test new cancer drugs for children in combination with certain existing adult cancer drugs or standard pediatric treatments.
• Requires pediatric cancer drug studies to gather specific data on dosing, safety, and effectiveness for different age groups.
• Changes when drug companies would pay a specific fee when using a priority review voucher.
• Requires the Food and Drug Administration (FDA) to create new guidelines for these changes within 12 months of the bill becoming law.